Your browser doesn't support javascript.
loading
Targeting gp100 and TRP-2 with a DNA vaccine: Incorporating T cell epitopes with a human IgG1 antibody induces potent T cell responses that are associated with favourable clinical outcome in a phase I/II trial.
Patel, Poulam M; Ottensmeier, Christian H; Mulatero, Clive; Lorigan, Paul; Plummer, Ruth; Pandha, Hardev; Elsheikh, Somaia; Hadjimichael, Efthymios; Villasanti, Naty; Adams, Sally E; Cunnell, Michelle; Metheringham, Rachael L; Brentville, Victoria A; Machado, Lee; Daniels, Ian; Gijon, Mohamed; Hannaman, Drew; Durrant, Lindy G.
Afiliação
  • Patel PM; Academic Department of Clinical Oncology, Division of Cancer & Stem Cells, University of Nottingham, Nottingham, UK.
  • Ottensmeier CH; Southampton Experimental Cancer Medicine Centre and Southampton University Hospitals, Faculty of Medicine, Southampton, UK.
  • Mulatero C; St James's University Hospital, Leeds, UK.
  • Lorigan P; Institute of Cancer Sciences, University of Manchester, The Christie NHS Foundation Trust, Manchester, UK.
  • Plummer R; Northern Institute for Cancer Research, Medical School, University of Newcastle-upon-Tyne and Wear, UK.
  • Pandha H; Faculty of Health and Medical Sciences, University of Surrey, Guildford, Surrey, UK.
  • Elsheikh S; University of Nottingham, School of Medicine Queen's Medical Centre, Nottingham, UK.
  • Hadjimichael E; University of Nottingham, School of Medicine Queen's Medical Centre, Nottingham, UK.
  • Villasanti N; University of Nottingham, School of Medicine Queen's Medical Centre, Nottingham, UK.
  • Adams SE; Scancell Limited, Academic Department of Clinical Oncology, University of Nottingham, Nottingham, UK.
  • Cunnell M; Academic Department of Clinical Oncology, Division of Cancer & Stem Cells, University of Nottingham, Nottingham, UK.
  • Metheringham RL; Scancell Limited, Academic Department of Clinical Oncology, University of Nottingham, Nottingham, UK.
  • Brentville VA; Scancell Limited, Academic Department of Clinical Oncology, University of Nottingham, Nottingham, UK.
  • Machado L; Scancell Limited, Academic Department of Clinical Oncology, University of Nottingham, Nottingham, UK.
  • Daniels I; Scancell Limited, Academic Department of Clinical Oncology, University of Nottingham, Nottingham, UK.
  • Gijon M; Scancell Limited, Academic Department of Clinical Oncology, University of Nottingham, Nottingham, UK.
  • Hannaman D; Ichor Medical Systems, Inc., San Diego, CA, USA.
  • Durrant LG; Academic Department of Clinical Oncology, Division of Cancer & Stem Cells, University of Nottingham, Nottingham, UK.
Oncoimmunology ; 7(6): e1433516, 2018.
Article em En | MEDLINE | ID: mdl-29872563
Palavras-chave
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Bases de dados: MEDLINE Tipo de estudo: Risk_factors_studies Idioma: En Revista: Oncoimmunology Ano de publicação: 2018 Tipo de documento: Article País de afiliação: Reino Unido
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Bases de dados: MEDLINE Tipo de estudo: Risk_factors_studies Idioma: En Revista: Oncoimmunology Ano de publicação: 2018 Tipo de documento: Article País de afiliação: Reino Unido